Publications

Fibrotech’s scientists have embarked on a medicinal chemistry program to identify, synthesize and develop new chemical entities that are suitable for therapeutic use as treatments for renal and cardiac indications. Fibrotech has established a solid foundation of intellectual property protection with 3 patents for new chemical entities and 2 for method of use.

FT 011, a Novel Synthetic Anti-Fibrotic Drug Attenuates the progression of Experimental Diabetic Nephropathy
hr
Improvement of left ventricular function due to a reduction of myocardial fibrosis following myocardial infarction using a purpose designed novel anti-fibrotic drug FT-011
hr
Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates